share_log

UBS Downgrades Cano Health to Sell, Lowers Price Target to $3.75

UBS Downgrades Cano Health to Sell, Lowers Price Target to $3.75

瑞银将Cano Health的评级下调为卖出,将目标股价下调至3.75美元
Benzinga ·  2023/11/17 10:48

UBS analyst Andrew Mok downgrades Cano Health (NYSE:CANO) from Neutral to Sell and lowers the price target from $12 to $3.75.

瑞银分析师安德鲁·莫克将Cano Health(纽约证券交易所代码:CANO)的评级从中性下调至卖出,并将目标股价从12美元下调至3.75美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发